Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nat Biotechnol 31, 3–4 (2013). https://doi.org/10.1038/nbt0113-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0113-3
- Springer Nature America, Inc.
This article is cited by
-
Generation of a chemical genetic model for JAK3
Scientific Reports (2021)
-
New partner for Galapagos JAK drug
Nature Biotechnology (2016)
-
Setback for JAK2 inhibitors
Nature Biotechnology (2014)